Group 1 - The core point of the article is that Duori Pharmaceutical announced a change in control, with three individuals forming a concerted action relationship to acquire a total of 23.68 million shares, representing 29.60% of the total share capital, at a price of 32.064 yuan per share, totaling 759 million yuan [1] - After the completion of this equity change, the three individuals will become the new actual controllers of the company, with Cui Zihao holding 14.90% of the shares as the largest shareholder, Wang Qingtai holding 5.00%, and Cao Xiaobing holding 9.70% [1] - The original shareholders, Xizang Jiakang and Deng Yong, have committed to renouncing their voting rights for 19.44 million shares (24.30% of the total share capital) until the completion of the tender offer [1] Group 2 - Wang Qingtai and Cao Xiaobing also plan to further increase their holdings through a partial tender offer for an additional 24.30% of the shares to solidify their control [1] - The equity change is still subject to the completion of share transfer registration and other procedures, meaning the change in control has not yet been finalized [1]
多瑞医药：控股股东拟变更为王庆太、崔子浩、曹晓兵（一致行动人）